Skip to main content

Table 1 Baseline demographic and clinical characteristics of the study population

From: Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer

Characteristic All patients Patients with VTE
(n = 605) (%) (n = 71) (%)
Median age, years 62 60
 25th–75th percentile 55–69 51–69
   < 60 237 (39.2) 32 (45.1)
   ≥ 60 368 (60.8) 39 (54.9)
Sex
 Male 352 (58.2) 40 (56.3)
 Female 253 (41.8) 31 (43.7)
ECGO PS
 0–1 424 (70.1) 41 (57.7)
 2–3 181 (29.9) 30 (42.3)
Tumor histology
 Adenocarcinoma 471 (77.9) 62 (87.3)
 Non-adenocarcinoma 134 (22.1) 9 (12.7)
  Squamous cell carcinoma 125 (20.7) 8 (11.3)
  Other NSCLC 9 (1.4) 1 (1.4)
Tumor Stage
 Localized 137 (22.6) 16 (22.5)
 Distant metastasis 468 (77.4) 55 (77.5)
EGFR gene
 Wild 361 (59.7) 49 (69.0)
 Mutated 244 (40.3) 22 (31.0)
KRAS gene
 Wild 543 (89.8) 61 (85.9)
 Mutated 62 (10.2) 10 (14.1)
Treatment during observation period
 Other treatment without TKI 220 (36.4) 27 (38.0)
 Other treatment with TKI 96 (15.9) 13 (18.3)
 TKI alone 141 (23.3) 11 (15.5)
 Chemotherapy alone 148 (24.5) 20 (28.2)
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, KRAS kitten rat sarcoma, NSCLC non-small cell lung cancer, TKI Tyrosine Kinase Inhibitor